JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on Sage Therapeutics (NASDAQ:SAGE) but lowers the price target from $28 to $23.

June 20, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan analyst Anupam Rama maintains an Overweight rating on Sage Therapeutics but lowers the price target from $28 to $23.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100